EMA Crunch Time For Shionogi’s Novel Antibiotic Cefiderocol
Executive Summary
The EU marketing application for cefiderocol that lost fast track status last July is now up for an opinion by the European Medicines Agency.
You may also be interested in...
Novartis, D&A Pharma Prepare For High-Stake EMA Meetings
Oral explanation meetings are due to take place this week for drug sponsors who have a final chance to address questions and concerns the European Medicines Agency has about their marketing applications.
Novartis, D&A Pharma Prepare For High-Stake EMA Meetings
Oral explanation meetings are due to take place this week for drug sponsors who have a final chance to address questions and concerns the European Medicines Agency has about their marketing applications.
Keeping Track Of User Fee Decisions And Filings: Adakveo, Brukinsa And Fetroja Mark Massive Week Of Novel Approvals
The latest news on US FDA user fee decisions and submissions to the agency.